Did you know that 1400 people die each day worldwide from sepsis? Thus the mortality rate of this common infectious disease still remains unacceptably high, making it one of the top 10 killers worldwide.
The mortality of sepsis could be halved if adequate treatment and the right antibiotics could be administered to patients within 48 hours of disease onset. Thus, hospital laboratories need a simple, easy to use, affordable and accurate molecular diagnostics device for the detection and identification of sepsis-causing bacteria.
Mobidiag has developed a World Record molecular test, capable of detecting 50 bacterial targets in a single assay. It provides the clinician with a comprehensive view on the cause of the infection, as well as flagging the presence of dangerous MRSA. All this in just three hours!
Annually, there are more than 2 million suspicions of viral central nervous system infections worldwide and the amount is rising due to progressive diagnostics Mobidiag's Prove-it™ Herpes assays enables the 8 viruses to be identified in 2 hours with the highest sensitivity. Current conventional molecular methods are often targeted for detection of a single virus and struggle with sensitivity issues.
The speed and accuracy of Mobidiag's test enables the pathogens to be identified 1-3 days earlier than with current conventional culturing methods. In fact, by administering correct antibiotics on time and reducing patient stays, a large University hospital is able to save approx. 0,3 - 0,5 M€ annually by using the Prove-it™ assays.
The uniqueness of Mobidiag’s products stems from the large number of recognizable pathogens, rapid results and a computerized approach that makes the test easy to handle.
With the newly released, CE-IVD-marked world record assay, Mobidiag has proved that it has tackled the technology risk that is involved in routine molecular diagnostics. The next challenge is to convert innovation into tangible benefits and business at the customer. Now Mobidiag is seeking an investment for the market penetration and new wave POC development.
Mobidiag offers investors the possibility to participate in the forthcoming revolution of diagnostics as new medical technologies spread from niche markets into routine use. By meeting the current clinical needs with Prove-it™ technology, Mobidiag offers stakeholders a compelling investment opportunity.